Redeye provides an update following SenzaGen’s Q4 2024 report.
Redeye comments on Lytix Biopharma's Q4 report. During the quarter, Verrica reported further progres...
Redeye provides its comment on Mendus’ Q4 2024 report.
Redeye updates its estimates and valuation following Mentice’s Q4 2024 report.
Strong EBIT of SEK 437m (ABGSCe 495m) in Q4 New targets: 15% ROE and total '25-'27 EBIT SEK 1.
Q4: Sales in line, but EBIT beat on strong GM We slightly cut our sales estimate, but raise adj.
Redeye returns following IRLAB's Q4 report and recent news in the company.
Sales decline continued, but solid cost control, comps ease from here Cut sales by 2%, EBIT by SEK 3...
Redeye comments in Invisio’s Q4-results which were in line with the preannounced results.
Q4 already pre-announced, orders +18% vs cons TAM updated from SEK 14bn to 25bn (+80%) Positive 2025...
Endomines successfully capitalized on the increased gold market prices during the second half of the...
Solteq’s Q4 performance mirrored its full-year trends, with declining sales but improved profitabili...
Raute’s Q4 margins were a bit lower than we estimated even if top line was higher than we expected.
Etteplan's Q4 results aligned with our estimates, with NRIs weighing on the figures.
Q4: EBITDA of NOK 5m vs ABGSCe NOK 6m Lower target range likely Estimates likely unchanged Q4: EBIT...
Adj. EBITA -11% vs ABG, -13% vs consensus Service companies drove the miss, products held up better ...
Redeye comments on a solid Q4 report in a soft market, showing that CombinedX is back among the qual...
Sales slightly above ABGSCe, ARR in line Limited consensus estimate revisions are likely Variable re...
Q4 sales -1% below our ests. at SEK 229m, for 12.5% org.
F&MT recovers from Q3 challenges Scandpower ends the year in style Decommissioning behind 5% cut to ...